Objectives: The hypothesis that BRO-1 selectively replaced the BRO-2 isoform of the Moraxella catarrhalis BRO β-lactamase was tested by examining the temporal distribution, antibiotic resistance and epidemiological characteristics of isolates from a long-term collection at a single locale.
Introduction
Soon after the first reports of a β-lactamase in Moraxella catarrhalis, phenotypic assays revealed differences in enzyme isoelectric points that accompanied a difference in β-lactamase enzymic activity. 1 The high and low activity variants, referred to as BRO-1 and BRO-2, respectively, differed primarily in amounts of enzyme produced and a slower in vitro rate of substrate metabolism by BRO-2 relative to BRO-1. 1, 2 The nucleotide sequence of the bro-2 allele differs from bro-1 by five nucleotides within the coding region, one of which causes an amino acid replacement of unknown significance. The upstream region of bro-1 includes 21 bp encompassing a second copy of a 16 bp repeat motif that is absent in bro-2 and is presumed to function as a promoter enhancer. 2 BRO-2 is relatively rare, invariably occurring in less than 15% of isolates. 1, 3 On the basis of sequence similarity between bro-2 and bro-negative isolates, Bootsma et al. 4 hypothesized that a bro-2-like allele was originally transferred into M. catarrhalis and that bro-1 was generated by a duplication in the promoter with subsequent spread enhanced by selection for more active enzymic activity via greater enzyme production.
This study examined evidence for the bro-1 replacement hypothesis, investigated the relationship between allelic types and antibiotic resistance phenotypes, documented the role of non-β-lactamase factors in penicillin resistance and tested the efficacy of a one-step, length-based PCR assay to distinguish bro alleles.
Materials and methods

Study population
Assays were conducted on 354 isolates composed of 25-50 randomly selected isolates from each of the 10 years (July 1984 to June 1994) repre-sented in a collection of M. catarrhalis from the Veterans Affairs Medical Center at Mountain Home, TN (VAMC). Details of the collection and methods for isolate selection, antibiotic testing, DNA extraction, and genotyping are given in Walker & Levy 5 and Walker et al. 6 β-Lactamase gene assays PCR primers amplified nucleotides -216 to +19 of the bla locus and encompassed the 21 bp difference that distinguishes the two bro alleles (GenBank U49269 and Z54180). Primer sequences were left: 5′-CAC-CCYGTRGGACAAGC-3′ and right: 5′-AATGACGGCGTTGCATC-3′. PCR products of 235 bp (bro-1) or 214 bp (bro-2) were distinguished on 2.0% agarose gels. Isolates that failed to generate a bro allele PCR product were tested for the presence of the bla gene using PCR primers encompassing 862 bp of the 945 bp of the coding region. Primer sequences were left: 5′-TTTGGATTGGGGTGAATGAT-3′ and right: 5′-TGGGGCTGGGTGATAAATAG-3′. PCR protocols consisted of 94°C for 10 min followed by 25 cycles of: 94°C for 30 s, 55°C for 60 s, 72°C for 40 s and ending with 72°C for 7 min. ATCC 43627, 43628 and 25238 were used as BRO-1, BRO-2 and BRO-negative controls, respectively. All negative PCRs were tested twice and DNAs were demonstrated to be suitable PCR substrates in control assays. Digoxigenin-labelled probes for dot blots were constructed by PCR using DNA from ATCC 43627 and BRO-1 clinical isolate 327.
Statistical analysis
Penicillin MICs for BRO-1 and BRO-2 samples were compared using ANOVA.
Results
The bro-2 allele, found in 13 of 354 isolates, comprised 2-10% of the samples from 1986 to 1991 but was absent during earlier and later sample years. BRO-2 was associated with seven different genotypes and showed evidence of spatial and temporal clustering of isolates with identical and related genotypes (Table 1) . For example, three 206BC BRO-2 isolates were recovered within a 15-day period and two were recovered from patients in the same ward. All three occurrences of genotype 441CC were BRO-2 and they were recovered within a 6-month span concurrently with the two BRO-2 isolates of the closely related (differing by one mutational step) genotype 113CC. Further, all BRO-2 isolates of genotypes 113CC and 441CC were isolated from patients in two wards. The pairwise number of differences between the remaining BRO-2 genotypes ranged from three to 12 mutational steps.
BRO-1 isolates showed significantly higher penicillin MICs than BRO-2 isolates (F = 6.51; df = 1, 266; P = 0.01; geometric means: BRO-1 = 3.29, BRO-2 = 1.24) with a minimum MIC of 0.25 mg/L for a β-lactamase-producing isolate (Table 2) . BRO-1 isolates also showed significantly higher rates of nitrocefin substrate hydrolysis compared with BRO-2 isolates, but there was no relationship between rate of hydrolysis and penicillin MIC (data not shown).
The nitrocefin disc assay for β-lactamase activity and the bro allele PCR assay showed correspondence in 98% (346/353) of the isolates. Seven penicillin-resistant isolates lacked PCR products but nitrocefin hydrolysis and bla probe hybridization showed the absence of a PCR product was not caused by the absence of a functional gene, suggesting that PCR failure probably arose from mismatches between primer and target sequences. For the purpose of detecting a β-lactamase gene, the bro allele PCR assay had a success rate of 97.4% (262/269) and it does not require restriction digestion of PCR products. Reduced susceptibility to penicillin also occurred in the absence of a β-lactamase as evidenced by 12 isolates with reduced susceptibility (MIC 0.06-0.25 mg/L) that tested negative for a β-lactamase in enzymic and molecular assays ( Table 2) . One isolate generated no PCR products and failed to hydrolyse nitrocefin (907, MIC = 0.50 mg/L), but its DNA hybridized to the probe derived from the clinical isolate and not to the ATCC probe. Thus, the β-lactamase 
Discussion
BRO-1 replacement hypothesis
Two observations from this study fail to support the hypothesis that BRO-2 was more common in the past and its frequency declined as a result of replacement by BRO-1. First, BRO-2 was absent in isolates from the early collection years, a period when β-lactamase producers were less common, 6 and second, when present, BRO-2 showed a sporadic, rather than declining temporal distribution. Incomplete collections render our analysis and data from other studies inadequate for detecting processes that preceded the early 1980s. Nevertheless, the presence of BRO-2 in diverse, but often rare phylogenetic lineages, combined with prior evidence that the transition to penicillin resistance was not mediated by population bottlenecks or a selective sweep, 5 suggests generation of bro-2 alleles by either recurrent mutation or spread via horizontal transmission. Phylogenetic and epidemiological associations among BRO-2 isolates suggest minor fluctuations in frequency reflect brief bouts of clonal expansion rather than long-term trends caused by selection. For example, temporal clusters of genetically identical BRO-2 isolates accounted for over half (8/13) of the BRO-2 isolates and these appeared to have arisen via patient-to-patient transmission. The frequency of BRO-2 isolates is probably an equilibrium balancing increases by mutation and clonal expansion with decreases caused by either genetic drift or selection. If BRO-1 is under positive selection then the sporadic and continued occurrence of BRO-2 may be explained by recurrent mutation and horizontal exchange, both of which are consistent with observations of BRO-2 in unrelated genotypes as shown in our study and in Bootsma et al. 7 Trimodality in the penicillin-susceptibility spectrum Trimodal patterns of penicillin MICs uncovered in earlier studies led to the hypothesis that the three peaks corresponded to BRO-negative, BRO-2 and BRO-1 strains. 6, 8, 9 The current survey has shown that that hypothesis was not correct but rather, the trimodality is caused by a unimodal pattern in BRO-negative isolates with a peak in the susceptible range (<0.03 mg/L) and bimodality within BRO-1 isolates with peaks at 1 and >16 mg/L (Table 2) .
Factors other than the characterized differences between BRO-1 and BRO-2 must underlie the BRO-1 bimodal pattern. Similar hypotheses of additional factors have been offered to explain the range of ampicillin MICs among β-lactamase producers 10 and the overlap in ampicillin MICs among BRO types. 3 
Non-β-lactamase-mediated resistance factors as MIC modifiers
Twelve β-lactamase-negative isolates, representing five different genotypes, displayed MICs with either reduced susceptibility or clinically-relevant penicillin resistance (≥0.25 mg/L). These strains tested negative for the presence of the bla gene by two independent PCR assays and a genomic dot blot assay, and they failed to hydrolyse nitrocefin. Penicillin MICs for these isolates ranged from 0.06 to 0.25 mg/L, conclusively demonstrating that non-β-lactamase resistance factors can confer clinical resistance in M. catarrhalis.
In Neisseria gonorrhoeae, non-β-lactamase-mediated penicillin resistance developed through the gradual accumulation of mutations, each leading to a minor reduction in susceptibility. These mutations gave rise to an altered penicillin-binding protein (PBP), enhanced efflux pumps, and decreased membrane permeability. [11] [12] [13] Altered PBPs confer resistance specifically to β-lactam agents, but altered efflux and permeability confer reduced susceptibility to non-β-lactam agents including macrolides. 12,13 Similar non-β-lactamase resistance mechanisms may underlie prior observations of antibiotic-specific changes in susceptibility in M. catarrhalis at the VAMC. For example, cefamandole resistance declined after the drug was no longer used at the medical centre, although resistance to penicillin and the proportion of β-lactamase producers continued to rise in the population. 6 Additionally, a significant temporal population trend toward increasing clarithromycin MICs was restricted to the β-lactamase producers, 6 a phenotype consistent with determinants conferring altered efflux or permeability. 
